What is the current valuation of the US Anthrax Vaccine Market?

The US Anthrax Vaccine Market was valued at 216.0 USD Million in 2024. Read More

What is the projected market size for the US Anthrax Vaccine Market by 2035?

The market is projected to reach 421.2 USD Million by 2035. Read More

What is the expected CAGR for the US Anthrax Vaccine Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 6.26%. Read More

Which companies are the key players in the US Anthrax Vaccine Market?

Key players include Emergent BioSolutions, GlaxoSmithKline, Sanofi Pasteur, Pfizer, Baxter International, Hoffmann-La Roche, Novartis, and Merck & Co. Read More

What are the main applications of anthrax vaccines in the market?

The main applications include Prevention, Post-Exposure Prophylaxis, and Research and Development. Read More

How much revenue is generated from the Prevention segment of the market?

The Prevention segment generated revenues between 108.0 and 210.0 USD Million. Read More

What is the revenue range for the Military end-use segment?

The Military end-use segment is expected to generate revenues between 70.0 and 140.0 USD Million. Read More

What distribution channels are utilized in the US Anthrax Vaccine Market?

Distribution channels include Direct Sales, Online Sales, Pharmacies, and Hospitals. Read More

What are the different formulation types available in the market?

Formulation types include Liquid, Lyophilized, and Suspension. Read More

Which target populations are prioritized in the US Anthrax Vaccine Market?

Target populations include Adults, Children, and High-Risk Individuals. Read More

US Anthrax Vaccine Market

ID: MRFR/Pharma/20408-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Anthrax Vaccine Market Research Report Information By Vaccine Type (Cell Free PA Vaccine, Anthrax Vaccine Adsorbed (AVA), Anthrax Vaccine Precipitated (AVP), and Live Attenuated Vaccine), By Applications (Animal Use and Human Use), and By Distribution Channel (Hospitals, Pharmacies, and Other Distribution Channels)—United States Market Forecast Till 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Prevention
  2. 4.1.2 Post-Exposure Prophylaxis
  3. 4.1.3 Research and Development
2. 4.2 Healthcare, BY End Use (USD Million)
  1. 4.2.1 Government Agencies
  2. 4.2.2 Military
  3. 4.2.3 Healthcare Institutions
  4. 4.2.4 Pharmaceutical Companies
3. 4.3 Healthcare, BY Distribution Channel (USD Million)
  1. 4.3.1 Direct Sales
  2. 4.3.2 Online Sales
  3. 4.3.3 Pharmacies
  4. 4.3.4 Hospitals
4. 4.4 Healthcare, BY Formulation Type (USD Million)
  1. 4.4.1 Liquid
  2. 4.4.2 Lyophilized
  3. 4.4.3 Suspension
5. 4.5 Healthcare, BY Target Population (USD Million)
  1. 4.5.1 Adults
  2. 4.5.2 Children
  3. 4.5.3 High-Risk Individuals
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Emergent BioSolutions (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 GlaxoSmithKline (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi Pasteur (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Baxter International (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Hoffmann-La Roche (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY END USE
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 US MARKET ANALYSIS BY FORMULATION TYPE
6. 6.6 US MARKET ANALYSIS BY TARGET POPULATION
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
17. 6.17 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
19. 6.19 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
21. 6.21 HEALTHCARE, BY TARGET POPULATION, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY TARGET POPULATION, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.2.2 BY END USE, 2026-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
  4. 7.2.4 BY FORMULATION TYPE, 2026-2035 (USD Million)
  5. 7.2.5 BY TARGET POPULATION, 2026-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Application (USD Million, 2026-2035)

Prevention
Post-Exposure Prophylaxis
Research and Development

Healthcare By End Use (USD Million, 2026-2035)

Government Agencies
Military
Healthcare Institutions
Pharmaceutical Companies

Healthcare By Distribution Channel (USD Million, 2026-2035)

Direct Sales
Online Sales
Pharmacies
Hospitals

Healthcare By Formulation Type (USD Million, 2026-2035)

Liquid
Lyophilized
Suspension

Healthcare By Target Population (USD Million, 2026-2035)

Adults
Children
High-Risk Individuals

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”